Pacific Biosciences (PACB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.14
- EPS surprise
- −2.41%
- Revenue surprise
- −0.50%
- Revenue
- $39.0M
- Revenue estimate
- $39.2M
- Reported
- Aug 5, 2026
Pacific Biosciences reported Q2 2026 results on August 5, 2026. The company posted a loss of $0.14 per share, matching the $0.14 estimate but listed as a 2.41% miss. Revenue of $39.0 million came in 0.50% below the $39.2 million consensus. Compared with Q2 2025, the loss was unchanged at $0.14, and revenue slipped 2% from $39.8 million.
Losses dominate the table. Only two of the last 20 quarters were profitable: Q3 2021 at $0.08 and Q4 2024 at $0.01. Full-year losses were $1.40 per share in 2022, $1.21 in 2023, $1.14 in 2024 and $1.84 in 2025. The 2025 total includes a $1.44 loss in Q1 2025, the largest in the table, while the other three quarters of 2025 were losses of $0.13 to $0.14. Annual revenue peaked here at $200.6 million in 2023, fell about 23% to $154.0 million in 2024 and reached $160.0 million in 2025. Pacific Biosciences beat the EPS estimate in 10 of the last 20 quarters.
Q3 results came between October 30 and November 7 in the past five years. That points to early November 2026 for the next report. It will show whether quarterly losses stay near the recent range.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.14 | −$0.14 | −2.41% | $39.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.14 | −$0.03 | +78.83% | $37.2M | SEC |
| Q4 2025 | Feb 12, 2026 | −$0.14 | −$0.13 | +9.53% | $44.6M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.15 | −$0.13 | +14.02% | $38.4M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.17 | −$0.14 | +18.98% | $39.8M | SEC |
| Q1 2025 | May 8, 2025 | −$0.19 | −$1.44 | −652.35% | $37.2M | SEC |
| Q4 2024 | Feb 13, 2025 | −$0.19 | $0.01 | +105.19% | $39.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.22 | −$0.22 | +0.32% | $40.0M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.23 | −$0.64 | −174.68% | $36.0M | SEC |
| Q1 2024 | May 9, 2024 | −$0.28 | −$0.29 | −5.26% | $38.8M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.29 | −$0.31 | −8.05% | $58.4M | SEC |
| Q3 2023 | Oct 30, 2023 | −$0.29 | −$0.26 | +10.13% | $55.7M | SEC |
| Q2 2023 | Aug 2, 2023 | −$0.32 | −$0.28 | +12.50% | $47.6M | SEC |
| Q1 2023 | May 2, 2023 | −$0.33 | −$0.36 | −8.50% | $38.9M | SEC |
| Q4 2022 | Feb 16, 2023 | −$0.36 | −$0.37 | −2.69% | $27.4M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.33 | −$0.34 | −2.50% | $32.3M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.34 | −$0.32 | +5.41% | $35.5M | SEC |
| Q1 2022 | May 4, 2022 | −$0.32 | −$0.37 | −15.59% | $33.2M | SEC |
| Q4 2021 | Feb 15, 2022 | −$0.28 | −$0.31 | −9.42% | $36.0M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.22 | $0.08 | +136.04% | $34.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Pacific Biosciences (PACB) last report earnings?
Pacific Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did PACB beat earnings estimates?
No. Pacific Biosciences reported EPS of −$0.14 for Q2 2026 against a −$0.14 estimate — a 2.41% miss.
How much revenue did PACB report last quarter?
Pacific Biosciences reported $39.0M in revenue for Q2 2026, against a consensus estimate of $39.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.